携胰岛素调控基因系统的载体构建及鉴定

目的：构建受胰岛素、葡萄糖双向调节的胰岛索分泌调控基因的载体。方法：1．用酚氯仿抽提法提取SD大鼠肝脏基因组DNA,用P1、P2为引物。PCR扩增胰岛素生长因子结合蛋白-1启动子(IGFBP-1);2.选用pUC118作为克隆载体,用分子克隆技术亚克隆三倍体葡萄糖反应元件(GLRE)3;3,运用基因重组技术将ICFBP-1启动子定向插入(GLRE)3的下游。结果：1.PCR扩增出420bp的目的DNA片断,与文献IGFBP-1 DNA大小一致;2．重组体序列分析显示,克隆的基因序列和文献报道的(GLRE)3及IGFBP-1基因序列一致。结论：成功构建携胰岛素调控基因系统的载体pUC118(GLRE)3-IGFBP-1。为1型糖尿基因治疗的进一步实验研究奠定了基础。     

关岭牛MyoD玉基因启动子报告质粒的构建及活性验证

为了克隆关岭牛MyoD玉基因启动子并验证其启动活性,根据GenBank中牛的MyoD玉基因序列设计PCR引物,用PCR技术扩增牛MyoD玉基因的启动子,构建重组克隆载体pUCmT-MyoD玉;并通过PCR扩增、限制性酶切、测序及生物信息学分析对阳性克隆进行鉴定;构建报告质粒pGL3-MyoD玉,并将其转染小鼠C2C12、3T3-L1细胞系,检测其24 h后的双荧光素酶活性。实验结果获得了关岭牛MyoD玉基因启动子,其序列长度为993 bp,并成功构建了MyoD玉启动子报告质粒;双荧光素酶活性检测表明pGL3-MyoD玉在小鼠C2C12细胞中的表达是pGL3空载体40.65倍,在小鼠3T3-L1细胞中的表达是空载体的1.13倍,MyoD玉启动子在小鼠C2C12细胞中的表达高于3T3-L1细胞(**p<0.01)。结果表明关岭牛MyoD玉基因启动子具有启动活性,在小鼠骨骼肌细胞中特异性表达。     

含三倍体葡萄糖反应元件的质粒的构建及序列分析

用酚氯仿抽提法提取SD大鼠肝脏的基因组DNA,PCR扩增单倍体葡萄糖反应元件（glre）。分别用SacⅠ酶单酶切glre、pUC118载体后,连接、转化,PCR筛选出含三倍体glre的质粒并测序。结果PCR扩增出51bp的目的DNA片段,与文献报道的葡萄糖反应元件glre的大小一致;连接转化后,经PCR筛选出三倍体glre,序列分析显示其基因序列和Genbank数据库中的glre基因一致。以上结果表明构建成功含三倍体glre的质粒,为构建具双向调节的胰岛素分泌调控基因质粒奠定了基础。     

FLT-1启动子荧光素酶报告基因重组体的构建和鉴定

目的：为探索FLT-1启动子靶向调控活性分析,克隆FLT-1启动子基因序列,构建并鉴定肿-1启动子调控的荧光素酶报告基因重组体pGL3-FLT—Basic—luc。方法：应用聚合酶链式反应（PCR）技术扩增FLT-1启动子序列,定向亚克隆至荧光素酶表达载体pGL3-Basic—luc中,构建含有正确目的基因的报告基因重组体pGL3-FIT—Basic—luc,通过限性内切酶酶切、PCR及测序进行鉴定。结果：通过酶切鉴定及基因测定证明,所克隆的基因产物与预期结果-致,序列无碱基突变。结论：成功构建了含有FLT-1启动子基因序列的荧光素酶报告基因真核表达载体,为下-步分析该启动子活性及血管疾病的基因治疗奠定基础。     

小鼠TIE2基因启动子的克隆及转录活性分析

克隆小鼠TIE2基因的启动子并分析其转录活性.设计并合成引物,以小鼠肝脏组织DNA为模板,巢式PCR扩增小鼠TIE2基因启动子区.将扩增获得的系列截短片段克隆入荧光素酶(Luc)报告基因表达载体pGL3-Basic中,构建系列启动子区转录活性报告质粒pGL3-TIE2-Luc.报告质粒与内参质粒共转染SVEC4-10、NIH3T3、HUVEC及NIT-1细胞系,48h后收获细胞检测双荧光素酶的表达情况.构建的pGL3-TIE2-Luc系列报告质粒经过酶切鉴定及DNA测序分析都显示正确;转染4种细胞系后进行双荧光素酶活性检测的结果表明,TIE2基因启动子区域(-2056-+1)具有较强的转录活性.成功构建小鼠TIE2基因启动子报告质粒,证实TIE2基因上游区域(-2056-+1)具有较强的启动子活性.     

肺炎支原体P1蛋白羧基端基因片段在大肠杆菌中克隆的研究

在大肠杆菌中克隆肺炎支原体P1蛋白羧基端基因片段,为P1蛋白基因片段的扩增、表达及探讨羧基端基因片段功能打基础.采用PCR扩增方法获取P1结构基因.扩增产物用SalI和EcoRI酶切消化,回收1kb大小的DNA片段并与pUC19DNA连接,转入大肠杆菌JM109菌株.用X-gal平板及质粒图谱分析方法筛选重组克隆株,再用限制性核酸内切酶酶切图谱分析鉴定.经PCR扩增MPDNA获得1条5.0kbDNA片段.重组质粒限制性内切酶指纹图谱显示出2条带,1条为pUC19载体DNA带,另1条是1kb的插入片段.实验获得肺炎支原体P1蛋白结构基因及含P1蛋白羧基端DNA片段的重组克隆株.     

人ACT1基因P7启动子的克隆及序列分析

克隆并测定人酰基辅酶A:胆固醇酰基转移酶1(ACAT1)基因P7启动子的序列,进一步探讨ACAT1基因表达的转录调控特点并分析其特异性转录位点。根据GenBank数据库提供的人A- CAT1基因P7启动子核苷酸序列,应用PCR方法从人单核细胞系THP-1扩增分离出ACAT1基因P7启动子全长片段,将PCR产物克隆入T载体,并对所获得的序列进行生物学信息分析。经琼脂糖凝胶电泳及直接测序鉴定,克隆的ACAT1基因P7启动子片段碱基序列与Gen Bank数据库一致。成功克隆了ACAT1基因P7启动子,为研究在动脉粥样硬化过程中AcAT1基因的转录调控机制奠定基础。     

胰岛素样生长因子结合蛋白-7基因的克隆和表达

IGFBP-7是胰岛素样生长因子结合蛋白(IGFBP)家族中的一员,具有一些抑癌基因的特征。利用重组PCR技术获得了IGFBP-7基因的全长编码区序列,并将其克隆到pcDNA3．1／His—Myc真核表达载体中,得到重组质粒pcDNA3．1／His—Myc—IGFBP-7。将该重组质粒瞬时转染人胚胎肾293T细胞,Westem-blot分析表明,IGFBP-7在293T细胞中获得了表达,为进一步研究IGFBP-7的功能奠定了基础。     

拟南芥NPR1基因的克隆与表达载体的构建

NPR1基因为植物抗病基因表达和系统获得性抗性中的一个关键基因。该文以DNA PCR扩增的方法,从拟南芥基因组DNA中克隆出NPR1基因,通过序列分析,所克隆的 NPR1 基因与报道的基因序列完全一致。将其构建成植物表达载体,为今后植物抗病基因工程的开展奠定了基础。     

Mip1对大鼠心肌细胞凋亡基因Bid转录调控作用的初探

目的:研究转录因子Mip1对大鼠心肌细胞H9C2凋亡相关基因Bid的转录调控作用.方法:以H9C2细胞基因组DNA为模板,扩增Bid核心启动子片段,将其克隆入荧光素酶报告基因质粒PGL3-Basic中,构建重组载体,并采用双酶切法、PCR法及基因测序对其进行鉴定.用脂质体转染法将该载体转入Mip1不同程度过表达的H9C2细胞,检测该细胞Bid基因启动子区的转录活性.结果:成功克隆Bid基因启动子区,双酶切、PCR和基因测序均显示PGL3-Basic-Bid promoter重组载体构建成功.荧光素酶相对活性检测显示在H9C2细胞中,随着Mip1转入的增多,Bid启动子区转录活性逐渐下降.结论:Mip1作为一个新的转录抑制因子,可以下调凋亡基因Bid的转录.     

The promoter of the human gene for insulin-like growth factor binding protein-1. Basal promoter activity in HEP G2 cells depends upon liver factor B1.

Characterization of the human insulin-like growth factor binding protein-1 (IGFBP-1) promoter was initiated to facilitate study of developmental and hormonal factors regulating IGFBP-1 production. The region immediately 5' to the IGFBP-1 mRNA capsite is typical of a eukaryotic promoter, with a TATA sequence beginning 28 base pairs (bp) and a CCAAT promoter element beginning 72 bp upstream from this capsite. A 1.3-kilobase insert containing the IGFBP-1 capsite and 1205 bp of this putative IGFBP-1 promoter region directs expression of the reporter gene chloramphenicol acetyltransferase (CAT) in an orientation-specific manner in transfected HEP G2 cells, and the capsite identified for the CAT mRNA is identical to that identified for native IGFBP-1 mRNA. These observations suggest that the 1.3-kilobase insert contains the IGFBP-1 promoter. This promoter was further characterized by deletion analysis, site-directed mutagenesis, gel mobility shift assays, and DNaseI protection assays. These studies identify the CCAAT box region as the major cis element involved in basal IGFBP-1 promoter activity in HEP G2 cells, demonstrate that increased basal promoter activity is associated with the binding of at least one HEP G2 nuclear factor to the CCAAT box region, and indicate that the DNA binding factor(s) responsible for increased basal promoter activity is related to liver factor B1. These observations suggest that liver B1 is the major trans-acting factor stimulating basal IGFBP-1 promoter activity in HEP G2 cells.     

Attenuation of insulin secretion by insulin-like growth factor binding protein-1 in pancreatic beta-cells

IGFBP-1 is involved in glucohomeostasis, but the direct action of IGFBP-1 on the beta-cell remains unclear. Incubation of dispersed mouse beta-cells with IGFBP-1 for 30min inhibited insulin secretion stimulated by glucose, glucagon-like peptide 1 (GLP-1) or tolbutamide without changes in basal release of insulin and in cytosolic free Ca(2+) concentration ([Ca(2+)](i)) and NAD(P)H evoked by glucose. In contrast, IGFBP-1 augmented glucose-stimulated insulin secretion in intact islets, associated with a reduced somatostatin secretion. These results suggest a suppressive action of IGFBP-1 on insulin secretion in isolated beta-cells through a mechanism distal to energy generating steps and not involving regulation of [Ca(2+)](i). In contrast, IGFBP-1 amplifies glucose-stimulated insulin secretion in intact islets, possibly by suppressing somatostatin secretion. These direct modulatory influences of IGFBP-1 on insulin secretion may imply an important regulatory role of IGFBP-1 in vivo and in the pathogenesis of type 2 diabetes, in which loss of insulin release is an early pathogenetic event.     

Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase

Insulin-like growth factor-binding protein-1 (IGFBP-1) is stimulated during intensive exercise and in catabolic conditions to very high concentrations, which are not completely explained by known regulators such as insulin and glucocorticoids. The role of AMP-activated protein kinase (AMPK), an important signaling system in lipid and carbohydrate metabolism, in regulating IGFBP-1 was studied in H4-II-E rat hepatoma cells. Arsenic(III) oxide and 5-aminoimidazole-4-carboxamide-riboside (AICAR) were used as activators. AICAR (150 microM) stimulated IGFBP-1 secretion twofold during a 5-h incubation (P = 0.002). Insulin (100 ng/ml) inhibited IGFBP-1 by 80% (P < 0.001), but this was completely abolished in the presence of 150 microM AICAR. The effect of dexamethasone in stimulating IGFBP-1 threefold was additive to the effect of AICAR (P < 0.001) and, in the presence of AICAR, was incompletely inhibited by insulin. In conclusion AMPK is identified as a novel regulatory pathway for IGFBP-1, stimulating secretion and blocking the inhibitory effect of insulin.